Literature DB >> 11900986

The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Hiroaki Ikeda1, Lloyd J Old, Robert D Schreiber.   

Abstract

Interferon-gamma (IFN gamma) is a cytokine that plays physiologically important roles in promoting innate and adaptive immune responses. The absence of IFN gamma production or cellular responsiveness in humans and experimental animals significantly predisposes the host to microbial infection, a result that validates the physiologic importance of this cytokine in preventing infectious disease. Recently, an additional role for IFN gamma in preventing development of primary and transplanted tumors has been identified. Although there now appears to be a consensus that IFN gamma promotes host responses to tumors, the mechanisms by which this cytokine achieves its effects remain unclear. In this review, we briefly discuss key issues of the molecular cell biology of IFN gamma and its receptor that are most relevant to IFN gamma-dependent anti-tumor effects and then focus on the data implicating IFN gamma as a critical immune system component that regulates tumor development. Potential mechanisms underlying IFN gamma's anti-tumor effects are discussed and a preliminary integrative model of IFN gamma's actions on tumors is proposed. Finally, the capacity of IFN gamma and lymphocytes to not only provide protection against tumor development but also to sculpt the immunogenic phenotype of tumors that develop in an immunocompetent host is presented and introduced as a "cancer immunoediting" process.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11900986     DOI: 10.1016/s1359-6101(01)00038-7

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  294 in total

1.  Natural killer cell-produced IFN-γ and TNF-α induce target cell cytolysis through up-regulation of ICAM-1.

Authors:  Ruipeng Wang; Jessica J Jaw; Nicole C Stutzman; Zhongcheng Zou; Peter D Sun
Journal:  J Leukoc Biol       Date:  2011-11-01       Impact factor: 4.962

Review 2.  The response of human dendritic cells to co-ligation of pattern-recognition receptors.

Authors:  Tanja Dzopalic; Ivan Rajkovic; Ana Dragicevic; Miodrag Colic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

3.  IFN-γ promotes graft-versus-leukemia effects without directly interacting with leukemia cells in mice after allogeneic hematopoietic cell transplantation.

Authors:  Yanping Yang; Hui Wang; Hui Yu; Beow Yong Yeap; Tingting Liang; Guanjun Wang; Tao Cheng; Yong-Guang Yang
Journal:  Blood       Date:  2011-08-11       Impact factor: 22.113

4.  Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma.

Authors:  Jo Eyles; Anne-Laure Puaux; Xiaojie Wang; Benjamin Toh; Celine Prakash; Michelle Hong; Tze Guan Tan; Lin Zheng; Lai Chun Ong; Yi Jin; Masashi Kato; Armelle Prévost-Blondel; Pierce Chow; Henry Yang; Jean-Pierre Abastado
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

5.  T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-gamma expression.

Authors:  Meixiao Long; Aaron M Slaiby; Adam T Hagymasi; Marianne A Mihalyo; Alexander C Lichtler; Steven L Reiner; Adam J Adler
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

6.  IGFBP-3 sensitizes prostate cancer cells to interferon-gamma-induced apoptosis.

Authors:  Peng Fang; Vivian Hwa; Brian M Little; Ron G Rosenfeld
Journal:  Growth Horm IGF Res       Date:  2007-08-24       Impact factor: 2.372

7.  Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22.

Authors:  Melody Abikhair; Hiroshi Mitsui; Valerie Yanofsky; Nazanin Roudiani; Channa Ovits; Teddy Bryan; Tatiana M Oberyszyn; Kathleen L Tober; Juana Gonzalez; James G Krueger; Diane Felsen; John A Carucci
Journal:  JCI Insight       Date:  2016-06-02

8.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

Authors:  Jianjun Gao; Lewis Zhichang Shi; Hao Zhao; Jianfeng Chen; Liangwen Xiong; Qiuming He; Tenghui Chen; Jason Roszik; Chantale Bernatchez; Scott E Woodman; Pei-Ling Chen; Patrick Hwu; James P Allison; Andrew Futreal; Jennifer A Wargo; Padmanee Sharma
Journal:  Cell       Date:  2016-09-22       Impact factor: 41.582

Review 9.  Interferon-gamma and cancer immunoediting.

Authors:  Gavin P Dunn; Hiroaki Ikeda; Allen T Bruce; Catherine Koebel; Ravi Uppaluri; Jack Bui; Ruby Chan; Mark Diamond; J Michael White; Kathleen C F Sheehan; Robert D Schreiber
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

10.  PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.

Authors:  Lisa M Kaminskas; David B Ascher; Victoria M McLeod; Marco J Herold; Caroline P Le; Erica K Sloan; Christopher J H Porter
Journal:  J Control Release       Date:  2013-03-15       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.